The District Court of Turin rejected Merck’s requests for a preliminary injunction, finding lack of inventive step of the claimed co-formulation of dorzolamid and timolol based on a prima facie assessment following the problem solution approach of the EPO Boards of Appeal.

Click here  for the full text of this case.

A summary of this case will be posted on


To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

Kluwer IP Law